OzemPIC, Wegovy and other weight loss medications are seized at the JFK International Airport Post facility.
CNBC
Copenhagen, Denmark – Europe’s pharmaceutical sector is preparing for a possible effect American definitions Hope for an industry exemption by US President Donald Trump fades.
The pharmaceutical industry has yet been exempt from commercial fees, but Trump certain Last week, he would soon impose definitions on the sector.
Medicines’ makers are now pressing the president to get a gradual approach to duties on imports to the United States, Reuters I mentioned Tuesday, quoting four sources familiar with the discussions. The sources said that the fees may not be announced on Wednesday, but it is likely to be inevitable.
The gradual implementation of the definitions of the sector can reduce the immediate financial strike and allow companies to transfer manufacturing in the United States. However, some companies have warned that lack of clarity already has negative secondary effects.
“For us, what is the most important not only the impact of customs tariffs, but also the effect it takes on the market,” Esther Begit, CEO of the Danish Biotechnology Company, told CNBC on Tuesday.
“When the customs tariff bring, it pays uncertainty, and when you are uncertain, it stops temporarily, stops innovation, publishes launch operations, and investments stop,” said Begit, whose company derives. About 30 % One of its sales from the United States, but it also strengthened its presence in the field of manufacturing in the country.
Denmark is one of the largest pharmaceutical and biotechnology centers in Europe, home to companies including the Wigofi maker Novo Nordsk And the vaccine product Bavari North – both of them have a large exposure to the United States
The head of Novo Nordisk Cnbc last week told the company that the company was not advancing before the Trump tariff was announced and that it instead focused on elastic stay.
“It is not much to predict.” “We focus on the laser on what we can influence.”
However, questions were asked about how the customs tariffs affect the sales of the United States for obesity and diabetes treatments in Novo-and the effects of our competition and the Zepbound maker Eli Lily. LUND will not be pressed on the sales sales of the weight that loses weight from American plants, and instead it indicates the preparation of the company’s “very important” manufacturing in the United States
‘no. One question about the minds of investors
The threat of definitions added to the uncertainty within the investment scene as well. Speaking to CNBC Monday, Emily Field, Head of European Pharmaceutical Research in Barclays, pointed to the customs tariff as “the first question about the minds of investors.”
Morten Bedkesov, Minister of Industry, Commercial and Financial Affairs of Denmark, told CNBC on Tuesday that he was connected to the country’s drug industry and companies on a broader scale on the potential impact of definitions on the heavy small economy.
“We, of course, are in a close dialogue box with them,” said Beskesov. He added: “It is our duty to bring them to discussions about the way the world changes. Many of them are leading companies in the world, so it is our duty to help them see the views of future markets.”
However, he indicated that it is unclear whether the Trump administration can be persuaded to back away from its protectionist policies, or make allowances for some sectors.
For companies like Novonesis, Baiget said it is a matter of watching events “very closely” – and learn about work if necessary.
“There are a lot of fluctuations, and there are many fast moving trends,” she said. “It is important to watch, and also learn how to store each other.”
https://image.cnbcfm.com/api/v1/image/108044272-1728325596986-FAKE-WEGOVY-JFK—1.jpg?v=1728325711&w=1920&h=1080
Source link